KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) EBT Margin (2016 - 2025)

Historic EBT Margin for Charles River Laboratories International (CRL) over the last 17 years, with Q3 2025 value amounting to 8.68%.

  • Charles River Laboratories International's EBT Margin fell 3600.0% to 8.68% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.55%, marking a year-over-year decrease of 133200.0%. This contributed to the annual value of 2.3% for FY2024, which is 117800.0% down from last year.
  • According to the latest figures from Q3 2025, Charles River Laboratories International's EBT Margin is 8.68%, which was down 3600.0% from 6.92% recorded in Q2 2025.
  • Charles River Laboratories International's 5-year EBT Margin high stood at 22.27% for Q4 2022, and its period low was 21.62% during Q4 2024.
  • Moreover, its 5-year median value for EBT Margin was 12.13% (2022), whereas its average is 10.53%.
  • In the last 5 years, Charles River Laboratories International's EBT Margin skyrocketed by 41900bps in 2022 and then crashed by -422200bps in 2024.
  • Over the past 5 years, Charles River Laboratories International's EBT Margin (Quarter) stood at 18.08% in 2021, then rose by 23bps to 22.27% in 2022, then decreased by -8bps to 20.59% in 2023, then crashed by -205bps to 21.62% in 2024, then skyrocketed by 140bps to 8.68% in 2025.
  • Its EBT Margin was 8.68% in Q3 2025, compared to 6.92% in Q2 2025 and 3.66% in Q1 2025.